Combination therapy of inhibitors of the epidermal growth factor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Goudar, R; Keir, S; Hjelmeland, M; Conrad, C; Traxler, P; Lane, H; Wang, XF; Bigner, DD; Friedman, HS; Rich, JN

Published Date

  • December 1, 2003

Published In

Volume / Issue

  • 9 / 16

Start / End Page

  • 6090S - 6090S

Published By

Pages

  • 1

International Standard Serial Number (ISSN)

  • 1078-0432

Conference Name

  • AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Conference Location

  • BOSTON, MASSACHUSETTS

Conference Start Date

  • November 17, 2003

Conference End Date

  • November 21, 2003